New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
06:10 EDTDTV, AZNStocks with implied volatility below IV index mean; AZN DTV
Stocks with implied volatility below IV index mean; AstraZeneca (AZN) 25, DirecTV (DTV) 14.
News For AZN;DTV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 13, 2014
07:16 EDTAZNBIT Congress to hold a conference
Subscribe for More Information
07:03 EDTAZNAstraZeneca initiates development program for Brilinta reversal agent
Subscribe for More Information
05:34 EDTAZNAstraZeneca, Isis Pharmaceuticals to co-develop oligonucleotide delivery methods
Subscribe for More Information
November 12, 2014
11:17 EDTAZNLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
07:35 EDTAZNAdvaxis submits IND application for ADXS-HPV Phase 1/2 study, MEDI4736
Advaxis (ADXS) announced that the company has submitted an Investigational New Drug application, or IND, to the FDA to conduct a Phase 1/2 study of ADXS-HPV alone or in combination with MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, for the treatment of advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. This follows the press release issued in July announcing the clinical trial collaboration between Advaxis and MedImmune, the global biologics research and development arm of AstraZeneca (AZN).
November 11, 2014
16:05 EDTAZNAmgen, AstraZeneca say Phase 3 brodalumab study met endpoints
Subscribe for More Information
15:43 EDTAZNLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
November 7, 2014
16:06 EDTDTVAT&T sees FY15 capex budget in $18B range
Subscribe for More Information
08:46 EDTDTVCord cutting accelerates as pay-TV loses 179K customers in Q3, WSJ reports
The pay-TV industry lost about 179K customers in Q3, which is steeper than the decline of 83K in the same quarter of last year, reported The Wall Street Journal, citing company reports and estimates from research firm MoffettNathanson. Companies that provide television service include AT&T (T), Verizon (VZ), DISH (DISH), Charter (CHTR), DirecTV (DTV), Cablevision (CVC), Comcast (CMCSA) and Time Warner Cable (TWC). Netflix (NFLX) and Amazon (AMZN) provide television and movie streaming services that compete with broadcast and cable television network offerings. Reference Link
November 6, 2014
15:03 EDTDTVDirecTV says need to offer smaller TV bundles versus a la carte options
Subscribe for More Information
14:42 EDTDTVDirecTV says still expects approximately 900K new Latin America subs in 2014
Subscribe for More Information
14:31 EDTDTVDirecTV sees FY14 adjusted EPS growth on high side of mid to high single digits
Subscribe for More Information
14:08 EDTDTVDirecTV says FCC AT&T review clock should begin mid-next week
Subscribe for More Information
07:35 EDTDTVDirecTV reports Q3 U.S. Gross Subscriber Additions 1.023M
Reports Q3 Latin America Gross Subscriber Additions 993K.
07:34 EDTDTVDirecTV reports Q3 EPS $1.33, consensus $1.30
Subscribe for More Information
06:35 EDTAZNAstraZeneca CEO says tax revisions cripple new Pfizer offer, Reuters says
Subscribe for More Information
05:51 EDTAZNAstraZeneca targets 2015 EPS to be no less than low end of 2014 range
AstraZeneca said, "For 2015, the Company plans to continue to selectively invest in its growth platforms and accelerating pipeline while managing overall costs. Assuming current exchange rates, the Company is targeting Core EPS for 2015 to be no less than the lower end of the range of the upgraded guidance for Core EPS for 2014 at actual exchange rates. Guidance for 2015 is expected to be provided with 2014 results on 5 February 2015."
05:50 EDTAZNAstraZeneca raises 2014 revenue growth outlook to low single digits at CER
AstraZeneca said 2014 revenue is now expected to increase in low single digits at CER, an upgrade to its previous guidance for revenue to be in line with 2013 at CER. The guidance assumes no U.S. Nexium generic in 2014. It added, "In light of the increase in revenue expectations for the year, the Company is accelerating its investments in its growth platforms and expanding pipeline. Core EPS for 2014 is now expected to decrease at around 10% at CER; better than anticipated in previous guidance. In addition, Core EPS for 2014 at actual exchange rates is expected to be impacted negatively by currency by around 5%, assuming current exchange rates."
05:49 EDTAZNAstraZeneca reports Q3 core EPS $1.05, consensus $1.04
Subscribe for More Information
05:37 EDTAZNAegerion acquires Myalept from AstraZeneca for $325M
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use